These results indicate that novel OSU-03012 compound may be a more potent inhibitor to PDK-1/AKT pathway than the currently potent inhibitor of PI3-K/AKT, LY294002 to treat childhood RMSs. This evidence concerns the gene PDK1 and Bannayan-Riley-Ruvalcaba syndrome.